Completed OBSERVATIONAL NCT05688306

To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment

A Real World Observational Study to Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Platelet-raising Therapy

Sponsor: Liaoning Cancer Hospital & Institute

Conditions Chemotherapy-induced Thrombocytopenia

Interventions Recombinant Human Interleukin-11 for Injection

Updated 4 times since 2023 Last updated: Jan 15, 2023 Started: Sep 2, 2020 Primary completion: May 16, 2022 Completion: May 16, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Chemotherapy-induced Thrombocytopenia and is currently completed. Liaoning Cancer Hospital & Institute leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Completed
Sep 2024 — Jan 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Feb 2023 — Jul 2024 [monthly]

Completed

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Liaoning Cancer Hospital & Institute

Data source: Liaoning Cancer Hospital & Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenyang, China